Abstract
Thiazolidinones, synthesized from multicomponent reactions of 2-heteroarylmethylamine, arenealdehydes and mercaptoacetic acid, have been tested against six yeasts, namely Candida albicans, C. parapsilosis, C. guilliermondii, Cryptococcus laurentii, Trichosporon asahii and Rhodotorula spp. The activities were expressed as minimum inhibitory concentrations (MIC) and the minimum fungicidal concentrations (MFC). The most affected yeasts were Rhodotorula spp and T. asahii. The cytotoxicities of the thiazolidinones against the fibroblast 3T3/NIH cell line are also described. The antifungal results and the low cytotoxicity of the compounds in this work provide good guides for the further development of active compounds.
Keywords: Antifungal activity, cytotoxic activity, Rhodotorula, thiazolidinones.
Medicinal Chemistry
Title:Antifungal Activity of 3-(heteroaryl-2-ylmethyl)thiazolidinone Derivatives
Volume: 10 Issue: 4
Author(s): Gabriela H. Marques, Alice Kunzler, Valeria D.O. Bareno, Bruna B. Drawanz, Hellen G. Mastelloto, Fabio R.M. Leite, Gustavo G. Nascimento, Patrícia S. Nascente, Geonir M. Siqueira and Wilson Cunico
Affiliation:
Keywords: Antifungal activity, cytotoxic activity, Rhodotorula, thiazolidinones.
Abstract: Thiazolidinones, synthesized from multicomponent reactions of 2-heteroarylmethylamine, arenealdehydes and mercaptoacetic acid, have been tested against six yeasts, namely Candida albicans, C. parapsilosis, C. guilliermondii, Cryptococcus laurentii, Trichosporon asahii and Rhodotorula spp. The activities were expressed as minimum inhibitory concentrations (MIC) and the minimum fungicidal concentrations (MFC). The most affected yeasts were Rhodotorula spp and T. asahii. The cytotoxicities of the thiazolidinones against the fibroblast 3T3/NIH cell line are also described. The antifungal results and the low cytotoxicity of the compounds in this work provide good guides for the further development of active compounds.
Export Options
About this article
Cite this article as:
Marques H. Gabriela, Kunzler Alice, Bareno D.O. Valeria, Drawanz B. Bruna, Mastelloto G. Hellen, Leite R.M. Fabio, Nascimento G. Gustavo, Nascente S. Patrícia, Siqueira M. Geonir and Cunico Wilson, Antifungal Activity of 3-(heteroaryl-2-ylmethyl)thiazolidinone Derivatives, Medicinal Chemistry 2014; 10 (4) . https://dx.doi.org/10.2174/15734064113099990030
DOI https://dx.doi.org/10.2174/15734064113099990030 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hypertension Impairs Cerebral Blood Flow in a Mouse Model for Alzheimer’s Disease
Current Alzheimer Research Metabolic Syndrome, Mild Cognitive Impairment and Dementia
Current Alzheimer Research Quinoline: An Attractive Scaffold in Drug Design
Mini-Reviews in Medicinal Chemistry Neuroinflammation, Oxidative Stress and the Pathogenesis of Alzheimers Disease
Current Pharmaceutical Design Cognitive Function and Heart Failure: The Role of the Adrenergic System
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Long Term Caregiving: Helping Families of Persons with Mild Cognitive Impairment Cope
Current Alzheimer Research Variability in Reward Responsivity and Obesity: Evidence from Brain Imaging Studies
Current Drug Abuse Reviews Raf Inhibitors as Therapeutic Agents Against Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design Neurokinin Peptides and Neurokinin Receptors as Potential Therapeutic Intervention Targets of Basal Ganglia in the Prevention and Treatment of Parkinsons Disease
Current Drug Targets Development and Potential Utility of Dual and Triple NK Receptor Antagonists
Current Topics in Medicinal Chemistry Are Cerebral Perfusion and Atrophy Linked in Multiple Sclerosis? Evidence for a Multifactorial Approach to Assess Neurodegeneration
Current Neurovascular Research Brain Derived Neurotrophic Factor and Cognitive Status: The Delicate Balance Among People Living with HIV, with and without Alcohol Abuse
Current HIV Research The Role of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease Diagnosis. Where are we Now?
Recent Patents on CNS Drug Discovery (Discontinued) The Protective Effects of Crocetin on Aβ<sub>1-42</sub>-Induced Toxicity in Ht22 Cells
CNS & Neurological Disorders - Drug Targets Recent Patents on PCSK9: A New Target for Treating Hypercholesterolemia
Recent Patents on DNA & Gene Sequences Amyloid Beta Hypothesis in Alzheimer's Disease: Major Culprits and Recent Therapeutic Strategies
Current Drug Targets Amyloid β -Protein Assembly as a Therapeutic Target of Alzheimers Disease
Current Pharmaceutical Design Folate-modified Graphene Oxide as the Drug Delivery System to Load Temozolomide
Current Pharmaceutical Biotechnology The Molecular Basis of Conantokin Antagonism of NMDA Receptor Function
Current Drug Targets